The Role of Sphingolipids in Cardiovascular Pathologies

被引:3
作者
Alessenko, A., V [1 ]
Lebedev, A. T. [2 ]
Kurochkin, I. N. [2 ]
机构
[1] Russian Acad Sci, Inst Biochem Phys, Ul Kosygina 4, Moscow 119334, Russia
[2] Moscow MV Lomonosov State Univ, Leninskie Gory, Moscow, Russia
关键词
cardiovascular diseases; markers; sphingolipids; ceramide; sphingosine-1-phosphate; PLASMA SPHINGOSINE-1-PHOSPHATE CONCENTRATION; (HDL)-ASSOCIATED SPHINGOSINE 1-PHOSPHATE; HIGH-DENSITY-LIPOPROTEINS; ACID SPHINGOMYELINASE; LIPIDOMIC ANALYSIS; KINASE-ACTIVITY; IN-VIVO; CERAMIDE; RECEPTOR; ISCHEMIA;
D O I
10.1134/S1990750819020021
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cardiovascular diseases (CVD) remain the leading cause of death in industrialized countries. One of the most important risk factors for atherosclerosis is hypercholesterolemia; its diagnostics is mainly based on regular analysis of the lipid profile, including the determination of total cholesterol, low and high density lipoprotein cholesterol, and triglycerides. However, in recent years, much attention has been paid to the crosstalk between metabolic pathways of cholesterol and sphingolipid biosynthesis. Sphingolipids are a group of lipids that include a molecule of sphingosine aliphatic alcohol. These include sphingomyelins, cerebrosides, gangliosides, ceramides, sphingosines, and sphingosine-1-phosphate. It has been found that sphingolipid catabolism is associated with cholesterol catabolism. However, the exact mechanism of this interaction still remains unknown. Ceramide attracts particular attention as a CVD inducer. Aggregated lipoproteins isolated from atherosclerotic zones were found to be enriched with ceramides. Ceramide and sphingosine levels increase after ischemia/reperfusion of the heart, in the infarction area and in the blood, as well as in hypertension. Sphingosine-1-phosphate (S-1-P) exhibits pronounced cardioprotective properties. Its quantity sharply decreased during ischemia and myocardial infarction. S-1-P predominated in the structure of high-density lipoproteins (HDL), where it has a significant impact on their multiple functions. An increase in ceramide and sphingosine and a decrease in S-1-P levels during progression of coronary heart disease may be an important factor in the development of atherosclerosis. It is proposed to use determination of sphingolipid levels in the blood plasma as markers for early diagnostics of cardiac ischemia and in hypertension in humans. Recently, intensive studies have been undertaken to create drugs that can correct S-1-P metabolism. The most successful developments include agents targeted to the S-1-P receptor, which mediates all S-1-P effects. Chromatography-mass spectrometry is proposed as the main method for testing these lipids.
引用
收藏
页码:122 / 131
页数:10
相关论文
共 91 条
  • [1] [Anonymous], 2004, J BIOL CHEM, V279, P997
  • [2] HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects
    Argraves, Kelley M.
    Argraves, W. Scott
    [J]. JOURNAL OF LIPID RESEARCH, 2007, 48 (11) : 2325 - 2333
  • [3] Metabolomics, Lipidomics and Pharmacometabolomics of Human Hypertension
    Au, Anthony
    Cheng, Kian-Kai
    Wei, Loo Keat
    [J]. HYPERTENSION: FROM BASIC RESEARCH TO CLINICAL PRACTICE, VOL 2, 2017, 956 : 599 - 613
  • [4] Aviram M, 1996, EUR J CLIN CHEM CLIN, V34, P599
  • [5] S1P lyase: a novel therapeutic target for ischemia-reperfusion injury of the heart
    Bandhuvula, Padmavathi
    Honbo, Norman
    Wang, Guan-Ying
    Jin, Zhu-Qiu
    Fyrst, Henrik
    Zhang, Meng
    Borowsky, Alexander D.
    Dillard, Lisa
    Karliner, Joel S.
    Saba, Julie D.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2011, 300 (05): : H1753 - H1761
  • [6] Effect of exercise duration on ceramide metabolism in the rat heart
    Baranowski, M.
    Zabielski, P.
    Blachnio, A.
    Gorski, J.
    [J]. ACTA PHYSIOLOGICA, 2008, 192 (04) : 519 - 529
  • [7] Baranowski M, 2011, ADV EXP MED BIOL, V721, P41, DOI 10.1007/978-1-4614-0650-1_3
  • [8] Ceramide selectively displaces cholesterol from ordered lipid domains (rafts) - Implications for lipid raft structure and function
    London, M
    London, E
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (11) : 9997 - 10004
  • [9] Beresewicz A, 2002, J PHYSIOL PHARMACOL, V53, P371
  • [10] Bielawska AE, 1997, AM J PATHOL, V151, P1257